Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab
- Sponsor
- Gruppo Italiano Studio Linfomi
- Study ID
- NCT00393107
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- rituximab — DRUG
- rituximab,fludarabine, cyclophosphamide — DRUG
Study Details
Purpose of this study was to assess the safety profile and the anti-lymphoma activity of the FC+R combination.
Key Dates
- Start date
- Mar 31, 2000
- Status verified
- Oct 2006
- Completion
- Aug 31, 2006
Study Design
- Enrollment
- 54 participants
- Allocation
- NON_RANDOMIZED
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Primary Outcome Measure
Toxicity during the treatment period
Related Studies
- A Long-term Extension Study of PCI-32765 (Ibrutinib)PHASE3 · Recruiting · Janssen Research & Development, LLC · Duarte, California
- Oncoquest-L Vaccine in Patients With Previously Untreated Stage III or IV, Asymptomatic, Non-bulky Follicular LymphomaPHASE2 · Not Yet Recruiting · XEME Biopharma Inc. · Newnan, Georgia
- Clonal Evolution in Follicular LymphomaRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Myeloablative Allo HSCT With Related or Unrelated Donor for Heme DisordersPHASE2 · Recruiting · Masonic Cancer Center, University of Minnesota · Minneapolis, Minnesota